ADCY6 Gene

ADCY6 Gene

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#1976D2; color:white;">ADCY6</th></tr>
<tr><td><strong>Full Name</strong></td><td>Adenylate Cyclase 6</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>ADCY6</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>12q13.12</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>113</td></tr>
<tr><td><strong>OMIM ID</strong></td><td>601302</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000174230</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>O43306</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Alzheimer's Disease, Parkinson's Disease, Cardiac Conduction Disorders, Diabetes</td></tr>
</table>
</div>

Overview

ADCY6 encodes adenylate cyclase 6 (AC6), also known as adenylyl cyclase 6, a calcium-inhibited isoform of the adenylyl cyclase family. AC6 is a membrane-bound enzyme that catalyzes the conversion of ATP to the second messenger cyclic AMP (cAMP), a crucial signaling molecule in numerous cellular processes. What makes AC6 unique among the ten mammalian adenylyl cyclase isoforms is its potent inhibition by intracellular calcium through a calmodulin-dependent mechanism, making it a critical sensor of calcium-cAMP crosstalk in cells[@calcium2003].

ADCY6 Gene

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#1976D2; color:white;">ADCY6</th></tr>
<tr><td><strong>Full Name</strong></td><td>Adenylate Cyclase 6</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>ADCY6</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>12q13.12</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>113</td></tr>
<tr><td><strong>OMIM ID</strong></td><td>601302</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000174230</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>O43306</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Alzheimer's Disease, Parkinson's Disease, Cardiac Conduction Disorders, Diabetes</td></tr>
</table>
</div>

Overview

ADCY6 encodes adenylate cyclase 6 (AC6), also known as adenylyl cyclase 6, a calcium-inhibited isoform of the adenylyl cyclase family. AC6 is a membrane-bound enzyme that catalyzes the conversion of ATP to the second messenger cyclic AMP (cAMP), a crucial signaling molecule in numerous cellular processes. What makes AC6 unique among the ten mammalian adenylyl cyclase isoforms is its potent inhibition by intracellular calcium through a calmodulin-dependent mechanism, making it a critical sensor of calcium-cAMP crosstalk in cells[@calcium2003].

The ADCY6 gene is expressed widely throughout the body, with particularly high levels in the heart, brain, kidney, and pancreas. In the central nervous system, AC6 plays essential roles in synaptic transmission, neuronal plasticity, and dopaminergic signaling, all processes central to neurodegenerative disease pathogenesis[@neuronal2008].

Molecular Biology and Structure

Gene Organization

The ADCY6 gene is located on chromosome 12q13.12 and spans approximately 30 kilobases. It contains 33 exons encoding a protein of 1,228 amino acids. The gene structure follows the conserved architecture of transmembrane adenylyl cyclases, with the coding sequence distributed across multiple exons[@isoforms2018].

The promoter region of ADCY6 contains several regulatory elements:

• CRE (cAMP Response Element): Mediates transcriptional regulation by cAMP
• TATA box: Core promoter element for transcription initiation
• GC-rich elements: Binding sites for Sp1 and other transcription factors
• Calcium-responsive elements: Control expression in response to calcium signaling

Protein Structure

The AC6 protein has the classic transmembrane adenylyl cyclase architecture:

Transmembrane Domains (M1-M12)

• N-terminal transmembrane region (M1-M6): Forms the first six transmembrane helices
• C-terminal transmembrane region (M7-M12): Forms the remaining six helices
• These two sets of six helices are connected by two cytoplasmic catalytic domains

Cytoplasmic Catalytic Domains

• C1a domain (approximately 300 aa): First cytoplasmic loop, contains the forskolin binding site and G protein interaction interface
• C2a domain (approximately 300 aa): Second cytoplasmic loop, forms a pseudodimer with C1a for catalytic activity

Regulatory Features

• Calmodulin-binding domain: Unique to AC6, mediates calcium inhibition
• Forskolin-binding pocket: Located at the interface of C1a and C2a
• G protein coupling sites: Interfaces with Gsα and Giα subunits
• Multiple phosphorylation sites: Serine and threonine residues for PKA-mediated regulation

Signaling Pathways

Primary cAMP/PKA Pathway

AC6 catalyzes the conversion of ATP to cAMP, initiating one of the most important second messenger cascades in eukaryotic cells:

Regulation by G Proteins

AC6 is regulated by multiple G protein subunits:

• Gsα: Stimulates AC6 activity, primary activator
• Giα: Inhibits AC6 activity, provides negative regulation
• Gβγ: Can modulate AC6 activity in certain contexts

Calcium Inhibition (Unique to AC6)

The defining feature of AC6 is its potent inhibition by intracellular calcium:

This calcium sensitivity allows AC6 to function as a bidirectional sensor, linking calcium signaling to cAMP production. This crosstalk is particularly important in neurons where calcium influx during synaptic activity modulates cAMP levels and downstream signaling[@calcium2003].

Downstream Effectors

The cAMP produced by AC6 activates multiple downstream targets:

Protein Kinase A (PKA)

• CREB phosphorylation: Activates transcription factor for gene expression
• Synaptic plasticity: Modifies ion channel function and receptor trafficking
• Metabolic regulation: Controls glycogen metabolism and glucose homeostasis
• Cytoskeletal dynamics: Regulates actin polymerization and neuronal morphology

Exchange Protein Activated by cAMP (Epac)

• Rap1 activation: Controls cell adhesion and junction formation
• ERK activation: Regulates cell growth and differentiation

Cyclic Nucleotide-Gated Channels (CNGC)

• Neuronal excitability: Affects action potential propagation
• Sensory signaling: Important for olfactory and retinal function

Role in Neurodegenerative Diseases

Parkinson's Disease

Dopaminergic Signaling

• Striatal signaling: In the striatum, AC6 is enriched in medium spiny neurons where it mediates dopamine receptor signaling. D1-type dopamine receptors couple to Gs proteins and activate AC6, while D2-type receptors couple to Gi proteins and inhibit AC6. This balance is crucial for motor control and is disrupted in PD[@dopamine2016].
• cAMP dysregulation: In PD models, alterations in adenylyl cyclase activity contribute to dopaminergic neuron dysfunction. Both increased and decreased cAMP signaling have been implicated depending on the cellular context and disease stage[@camp_neuronal2020].
• LRRK2 interaction: Recent research suggests crosstalk between LRRK2 kinase activity and cAMP signaling. LRRK2 mutations associated with familial PD may affect dopaminergic neuron function through adenylyl cyclase modulation[@lrrk22021].

Calcium Dysregulation

• Pacemaker activity: Dopaminergic neurons in the substantia nigra exhibit rhythmic calcium oscillations that drive their pacemaking activity
• Calcium-cAMP crosstalk: AC6's calcium sensitivity places it at the nexus of this dysregulation
• Vulnerable neurons: The specific vulnerability of dopaminergic neurons may relate to their reliance on calcium-cAMP signaling for survival[@calcium_pd2022]

Neuroprotection Strategies

• cAMP-enhancing strategies: Increasing cAMP signaling through phosphodiesterase inhibition or direct AC activation may protect dopaminergic neurons
• Calcium modulation: Reducing calcium dysregulation may normalize AC6 function
• G protein-coupled approaches: Targeting upstream receptors that modulate AC6 activity

Alzheimer's Disease

Synaptic Plasticity

• LTP induction: cAMP/PKA signaling is required for long-term potentiation, the cellular basis of learning and memory
• CREB activation: Phosphorylated CREB activates gene transcription necessary for memory consolidation
• Synaptic strengthening: PKA modulates AMPA receptor trafficking and function

Amyloid and Tau Pathology

AC6 may interact with key AD pathological features:

• APP processing: cAMP/PKA signaling can influence amyloid precursor protein processing
• Tau phosphorylation: PKA can phosphorylate tau at multiple sites relevant to tangle formation
• Neuronal survival: cAMP signaling provides anti-apoptotic signals that may be compromised in AD

Neuroinflammation

• Microglial modulation: cAMP inhibits microglial pro-inflammatory cytokine release
• Neuroprotection: Anti-inflammatory effects may slow disease progression

Dystonia-Parkinsonism

Mutations in GNAL (encoding Golf, the Gs protein that couples dopamine receptors to AC) cause dystonia-Parkinsonism syndrome, highlighting the importance of AC-cAMP signaling in these disorders. While ADCY6 mutations are not a common cause of these conditions, the shared signaling pathway implicates AC6 in their pathophysiology[@gnal2015].

Expression Pattern

Central Nervous System

AC6 is expressed throughout the brain:

• Cerebral cortex: Pyramidal neurons in layers II-VI
• Hippocampus: CA1-CA3 pyramidal cells, dentate gyrus granule cells
• Basal ganglia: Striatal medium spiny neurons, substantia nigra dopaminergic neurons
• Cerebellum: Purkinje cells, granule cells
• Hypothalamus: Neuroendocrine neurons
• Brainstem: Various nuclei including the locus coeruleus

Peripheral Tissues

Highest peripheral expression is in:

• Heart: Cardiac myocytes, sinoatrial node, atrioventricular node
• Kidney: Renal tubules, glomerular cells
• Pancreas: Beta cells (insulin-secreting cells)
• Liver: Hepatocytes
• Adipose tissue: Both brown and white adipocytes
• Lung: Pulmonary epithelium

Subcellular Localization

• Plasma membrane: Integral membrane protein
• Lipid rafts: Enriched in membrane microdomains
• Synaptic membranes: Present in both pre- and postsynaptic densities
• Cytosolic domains: Catalytic domains face the cytoplasm

Therapeutic Implications

Clinical Applications

Current and potential therapeutic applications of AC6 modulators:

| Drug/Approach | Target | Status | Indication |
|--------------|--------|--------|-------------|
| Forskolin | AC (direct activator) | Preclinical | Cognitive enhancement |
| PDE inhibitors | cAMP breakdown | Approved | Various |
| cAMP analogs | PKA activation | Research | Neuroprotection |
| Gene therapy | AC6 expression | Research | Heart failure |

Challenges for CNS Applications

• Blood-brain barrier: Many small molecule modulators cannot penetrate the CNS
• Isoform specificity: Developing AC6-selective modulators is challenging due to conserved catalytic domains
• Tissue specificity: Cardiac and neuronal effects may be difficult to separate
• Bidirectional effects: Both increased and decreased cAMP may have therapeutic benefit depending on context

Future Directions

• Brain-penetrant AC6 modulators: Developing compounds that can access the CNS
• Allosteric modulators: Targeting regulatory domains rather than the conserved catalytic site
• Gene therapy: Viral vector-mediated AC6 delivery or knockdown
• Combination approaches: Targeting AC6 signaling alongside other disease pathways

Animal Models

Genetic Models

• Adcy6 knockout mice: Viable and fertile, with cardiac phenotypes including altered heart rate and contractility
• Conditional knockouts: Tissue-specific deletion models to study CNS function
• Transgenic overexpression: Cardiac and neuronal overexpression models

Phenotypic Characteristics

AC6-modified mice exhibit:

• Altered cardiac function
• Modified stress responses
• Changes in learning and memory
• Modified metabolic responses
• Altered pain sensitivity

Disease Models

AC6 modulators have been tested in:

• MPTP-induced parkinsonism
• 6-OHDA lesion models
• Transgenic AD models
• Cerebral ischemia models

Pathway Diagram

Key Publications

See Also

• [Adenylate Cyclase Family](/entities/adenylate-cyclases)
• [cAMP Signaling Pathway](/mechanisms/camp-signaling)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Dopamine Receptors](/entities/dopamine-receptors)
• [G Proteins](/entities/g-proteins)
• [LRRK2](/entities/lrrk2)
• [Substantia Nigra](/brain-regions/substantia-nigra)
• [Striatum](/brain-regions/striatum)
• [Cyclic AMP](/entities/camp)

External Links

• [NCBI Gene: ADCY6](https://www.ncbi.nlm.nih.gov/gene/113)
• [UniProt: O43306](https://www.uniprot.org/uniprotkb/O43306)
• [Ensembl: ADCY6](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000174230)
• [GeneCards: ADCY6](https://www.genecards.org/cgi-bin/carddisp.pl?gene=ADCY6)
• [IUPHAR: Adenylyl Cyclases](https://www.guidetopharmacology.org/GRID/FamilyReceive?_prt_id=102)
• [OMIM: ADCY6](https://omim.org/entry/601302)